Six months shy of the PDUFA date for its oral, selective glucocorticoid receptor antagonist relacorilant to treat platinum-resistant ovarian cancer, Corcept Therapeutics Inc. reported a 35% reduction in the risk of death, meeting the second primary endpoint of overall survival after reaching statistical significance with progression-free survival last March. Read More

The economic and societal implications of the underfunding of women’s health finally reached the agenda of the World Economic Forum (WEF), with the launch at the 2026 annual meeting in Davos, Switzerland, this week of the inaugural Women’s Health Investment Outlook. The neglect of women’s health is not only a public health issue, but also “a market inefficiency on a global scale,” the WEF report said. Read More

Erasca Inc. priced an upsized public offering to raise $225 million to fund development of its therapies for patients with RAS/MAPK pathway-driven cancers. Read More

The structurally similar cytokines IL-2 and IL-15, and their shared beta subunit CD122, are keeping developers busy across a range of indications. Though some scientific confusion has plagued the space historically, drug candidates have drawn deals and Wall Street interest aplenty. Amgen Inc., Novartis AG, and Incyte Corp. are among those who’ve made their interest known. Read More

Lexicon Pharmaceuticals Inc. announced that it received no objections from the U.S. FDA to move pilavapadin, its non-opioid candidate for diabetic peripheral neuropathic pain, into phase III study, pushing company shares up near 20% on the day. Read More

On the heels of more positive early data from the lead program derived from its tumor-activated T-cell engager (TRACTr) platform, Janux Therapeutics Inc. inked a collaboration with Bristol Myers Squibb Co. that comes with $50 million in up-front and near-term milestone payments, with the possibility of up to $800 million more tied to development, regulatory and commercial milestones. Read More

Another day, another insider trading settlement involving a biopharma company employee. This time the U.S. SEC settlement is with Mohit Verma, who was a researcher and associate director of immunology at the San Diego-based Infinitybio Inc. at the time of the alleged violative trading activity. Read More

In a move that could dramatically shorten some clinical development timelines for drugs targeting multiple myeloma, the U.S. FDA issued a draft guidance on the potential use of minimal residual disease and complete response to support accelerated approvals, following the recommendation of the agency’s Oncologic Drugs Advisory Committee, which voted 12-0 in favor of the change in April 2024. Read More

New hires and promotions in the biopharma industry, including: Angelini, Crystalys, Human Continuum, LB, Ocular, Odyssey, Variant Bio, Zura. Read More

Biopharmas raising money in public or private financings, including: Engene, Ervimmune, Ocugen, Think, Vivos. Read More

Biopharma happenings, including deals and partnerships, and other news in brief: Genentech, Hygtia, Immedica, Insilico, Lisata, Kuva, Neurocrine, Qilu. Read More

Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Intrabio, Ionis, Opna, Otsuka, Ouro, Scynexis, Veloxis, Wugen. Read More